MCO vs STRO · P/E 33, rev $7.72B vs rev $62.0M
Moodys Corporation (MCO) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Moodys Corporation (MCO) is a financial data & stock exchanges company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported MCO revenue for 2025-12-31 was $7.72B. Net income was $2.46B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. MCO currently screens at market cap $79.69B and trailing P/E 32.7.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
MCO currently screens at market cap $79.69B and trailing P/E 32.7. STRO currently screens at market cap $470.8M.
Not investment advice. Open the MCO and STRO stock pages for the full models.
Not investment advice.